Navigation Links
Treatment With Prolia® (denosumab) Associated With Significantly Greater Adherence, Compliance and Persistence Compared to Alendronate
Date:3/23/2011

ures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as we may have believed at the time of entering into such relationship. Also, we or others could identify safety, side effects or manufacturing problems with our products after they are on the market. Our business may be impacted by government investigations, litigation and products liability claims. We depend on third parties for a significant portion of our manufacturing capacity for the supply of certain of our current and future products and limits on supply may constrain sales of certain of our current products and product candidate development.

In addition, sales of our products are affected by the reimbursement policies imposed by third-party payors, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment as well as U.S. legislation affecting pharmaceutical pricing and reimbursement. Government and others' regulations and reimbursement policies may affect the development, usage and pricing of our products. In addition, we compete with other companies with respect to some of our marketed products as well as for the discovery and development of new products. We believe that some of our newer products, product candidates or new indications for existing products, may face competition when and as they are approved and marketed. Our products may compete against products that have lower prices, established reimbursement, superior performance, are easier to administer, or that are otherwise competitive with our products. In addition, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors and th
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Prolia® (denosumab) Open-Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Five Years of Treatment With Similar Safety Profile Observed in Pivotal Trial
2. Study Demonstrates Relationship Between Subcutaneous IgG (SCIg) Dosage and Clinical Outcomes With Hizentra® Treatment in Patients With Primary Immunodeficiencies
3. AstraZeneca Initiates Phase III Clinical Programme Evaluating NKTR-118 for Treatment of Opioid-Induced Constipation
4. Optimer Pharmaceuticals Announces Issuance of Key Patent Covering Fidaxomicin Methods of Use as a Treatment of Clostridium difficile infection
5. The Balance-Based Torso-Weighting® Treatment for Multiple Sclerosis Receives a NIH Recovery Act Grant
6. Los Angeles Dentist, Dr. Kevin Sands, Uses the Latest Technologies to Provide VIP Services and Treatments for His Patients
7. International Prostate Cancer Treatment Expert Dr. David B. Samadi Supports Kenyan Minister of Medical Services, Peter Anyang Nyongos Decision to Travel to the U.S. for Prostate Cancer Treatment
8. Practice Guidelines Confirm Utility of Endoscopic Radiofrequency Ablation (RFA) for the Treatment of Barretts Esophagus
9. Pew Applauds Introduction of Preservation of Antibiotics for Medical Treatment Act of 2011
10. Tris Announces NDA Acceptance of Extended Release Carbinoxamine Oral Suspension for the Treatment of Allergies in Kids Two Years and Older
11. Genus Oncology, LLC Announces Orphan Drug Status for GO-203-2c for Treatment of Pancreatic Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 11, 2014 On Thursday, ... 0.52%, the Dow Jones Industrial Average finished the day 0.42% ... down 0.41%. The losses were broad based as eight out ... 500 Health Care Sector Index ended the day at 711.88, ... last one month. Investor-Edge has initiated coverage on the following ...
(Date:7/11/2014)... July 11, 2014 Neurelis, Inc. ("Neurelis") today ... end the option held by Biotie to purchase Neurelis, ... of NRL-1 (intranasal diazepam) for pediatric and adult epilepsy ... the past year, Biotie has advanced the development program ... the pivotal clinical work required for NDA submission to ...
(Date:7/10/2014)... -- Integrated Silicon Solution, Inc. (Nasdaq: ISSI ... solutions, today announced that it will host its earnings ... a.m. Pacific Time (10:00 a.m. Eastern Time) to discuss ... quarter ended June 30, 2014. To access ... a.m. Pacific time on July 24, 2014.  The participant ...
Breaking Medicine Technology:Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 2Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 4Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3
... Inc. (Nasdaq: BIOD ) will issue its third ...  Following the release of the company,s financial results, Biodel,s senior ... and provide an update on the company,s progress.August 4, 2011 ... be distributed4:15 pm EDT: , Conference call participants should dial:+1 ...
... Reportlinker.com announces that a new market research ... Insulin- Western Europe ... package contains 14 insulin market analyses from ... Denmark, Finland, France, Germany, Ireland, Italy, the ...
Cached Medicine Technology:Insulin- Western Europe 2
(Date:7/11/2014)... Riverside Health System became the first provider of Community- ... and now, in partnership with Williamsburg Landing, will offer its ... Newport News region. , Also known as life care at ... adults who wish to remain in their homes but want ... services as well as control over the cost of long-term ...
(Date:7/11/2014)... scientists have been trying to unravel mechanisms that guide ... that generate all blood cells including our immune system. ... because they can only be found in the bone ... a culture dish. Now a group of scientists from ... (Technische Universitt Dresden) was able to generate a mouse ...
(Date:7/11/2014)... 2014 WWTrek Human Outreach Project ... Community in Tanzania. Opened in 2012, the KKC is now ... cows. HOP Founder, Dean Cardinale, started the KKC to create ... orphaned children he encountered while running treks on Tanzania's Mount ... who have all made astounding progress in school over the ...
(Date:7/11/2014)... Francisco shows that an "expressive therapy" group intervention ... with HIV disclose their health status and improves ... quality of their relationships., "Medication alone is totally ... Machtinger, MD, director of the Women,s HIV Program ... are on effective antiretroviral therapy but far too ...
(Date:7/11/2014)... 2014 Recently, iFitDress.com, a leading online ... has released its new collection of evening dresses ... has announced that all these beautiful items are provided ... of the special offer is July 22. , ... pay close attention to customer satisfaction. On the company’s ...
Breaking Medicine News(10 mins):Health News:Riverside and Williamsburg Landing Partner to Offer First of Its Kind Service to Virginians Who Want to Age in Place 2Health News:Riverside and Williamsburg Landing Partner to Offer First of Its Kind Service to Virginians Who Want to Age in Place 3Health News:Riverside and Williamsburg Landing Partner to Offer First of Its Kind Service to Virginians Who Want to Age in Place 4Health News:Opening-up the stem cell niche 2Health News:Human Outreach Project Sees Incredible Progress in the Kilimanjaro Kids Community 2Health News:'Expressive therapy" intervention assists women living with HIV 2Health News:Worldwide Chic Ladies Can Buy Cheap Evening Dresses at iFitDress.com 2
... Windows Vista, Adobe Flash 10 and high-availability failover support. , ... ... today announced the release of the latest version of the industry ... of CoolSign further builds on its existing enterprise-based, robust feature set, ...
... 2009 As Zimbabwe continues to confront a,cholera ... a new,World Vision project supported by the Procter ... Drinking Water Program is underway, providing Zimbabweans with ... families and their,communities. , ...
... a limited edition beauty bag filled with products as ... Wash. and NEW YORK, Feb. 24 Beauty.com, Inc., ... DSCM ), announces Shoshanna Gruss as their ... program. Beginning February 25th, the exclusive Shoshanna-designed beauty case ...
... Them Crazy While They Work...30,000+ Dentists Converge in Chicago ... being issued by the Chicago Dental Society:Who: The ... members to find out some wacky, unusual, and just ... their chair.As we countdown to CDS,s annual Midwinter Meeting, ...
... dental techniques, , , TUESDAY, Feb. 24 (HealthDay News) -- ... and the development of skin and the nervous system ... University researchers have found. , Their discovery about the ... methods of repairing damaged enamel and preventing cavities, restoring ...
... promiscuity, experts stress, , , TUESDAY, Feb. 24 (HealthDay News) -- ... have sex, but a new study provides another suggestion that ... and teenage sexual activity. , The findings indicate that ... more likely to copy or emulate what they hear," said ...
Cached Medicine News:Health News:Procter & Gamble and World Vision Equip and Empower Zimbabweans in Fight Against Cholera 2Health News:Procter & Gamble and World Vision Equip and Empower Zimbabweans in Fight Against Cholera 3Health News:NY Fashion Designer Shoshanna Creates Exclusive Spring Bag for Beauty.com 2Health News:NY Fashion Designer Shoshanna Creates Exclusive Spring Bag for Beauty.com 3Health News:Top 5 Most Annoying Dental Patient Behaviors 2Health News:Scientists Find Gene for Tooth Enamel 2Health News:'Degrading' Lyrics Linked to Teen Sex 2Health News:'Degrading' Lyrics Linked to Teen Sex 3
... Alert Detection Reagents provide molecular labs a ... assays. By using our MGB technology, combined ... is now able to provide molecular labs ... sequences of specific organisms or genetic mutations ...
... latest and most advanced fecal occult blood ... An immunochemical FOBT (iFOBT) with high specificity ... to detect bleeding associated with more cancers ... of its superior specificity for lower GI ...
AUTION ELEVEN is the eleventh model of AUTION series which is ideal for use in small-to-medium-sized hospitals and clinics with its smart design and features....
Drugs of Abuse (DoA) Array is used for in-vitro diagnostic tests for the qualitative determination of the parent molecule and metabolites of drugs in human urine....
Medicine Products: